Navigation Links
Using Internal Communications to Help Build a Credible External Message Regarding New Pharmaceutical Products
Date:9/17/2010

CHAPEL HILL, N.C., Sept. 17 /PRNewswire/ -- For Pfizer, a key success factor in bringing Viagra successfully to market involved effectively naming and clarifying the condition that the drug was designed to treat. In this process, the brand team was able to shift the nomenclature for the condition from "impotence" (with its negative connotations and somewhat judgmental overtone) to "erectile dysfunction" (more clinical-sounding) to "ED" (casual and conversationally appropriate).

Leading biopharma companies have employed similar naming and communication strategies in introducing other first-in-class therapies for new or socially sensitive conditions like benign prostatic hypertrophy, social phobia, PMS, panic attack, insomnia, restless legs, overactive bladder, HIV and fibromyalgia.

A new Best Practices, LLC benchmarking report, Best Practices for Internal Communications Regarding Brands & Disease State, examines how companies communicate at the brand and disease state levels in order to educate employees internally and build a consistent, credible external message surrounding new products. Comprising in-depth surveys of 32 top biopharma companies and a series of executive interviews, this study will enable marketing and brand team leaders to implement the type of well-timed and well-targeted communications strategies essential for cementing both the medical and commercial framework for a new product's market entry and supporting its overall success as a brand.

Key topics covered in this research include:

  • Ten best practices for internal disease state communication excellence
  • Effective communication channels & use of new communication technologies
  • Timing of communication activities by product development phase
  • Advantages & disadvantages of employee message segmentation
  • Tracking internal message effectiveness
  • Preventing sensitive-information leaks
  • Using KOLs to influence employees
  • Special challenges for products treating socially sensitive conditions or diseases, first-in-class products, or new disease states or conditions
  • Needs creation marketing tactics

To learn more about this report, including information about the research participants, key findings and sample best practices, please download a complimentary excerpt and study overview at: http://www3.best-in-class.com/rr1022.htm.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC serves 48 of the world's 50 top pharmaceutical companies.  For 17 years, we have conducted work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies.  For more information about the company, go to www.best-in-class.com.


'/>"/>
SOURCE Best Practices, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
2. Avicena Scientific Collaborator Advances Program for Using Energy Enhancing Molecules to Treat Neuromuscular Diseases
3. Researchers Identify Virus Possibly Responsible for Declining Honeybee Population Using 454 Sequencing Technology from Roche
4. Large Blinded Clinical Study Achieves High Accuracy for the Diagnosis of Melanoma Using In Vivo Confocal Microscopy
5. Hopkins Report: Focusing on Family Planning Lessens HIV Impact
6. EnVivo Pharmaceuticals Announces Progress on Major Drug Programs Focusing on Alzheimers, Schizophrenia and Huntingtons Diseases
7. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
8. Harris Methodist Fort Worth Hospital Using Bubbles to Help Babies Breathe
9. Positive Results Published Using AtriCure Minimally Invasive Products
10. Universite de Montreal Researchers Simulate Worlds Largest Heart Model Using SGI Technology
11. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:10/2/2017)... announces the European launch of their new low volume, high throughput ... Cambridge, U.K on October 4th. The new ... unprecedented speed and sensitivity while using far less sample volume through ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Yisrayl Hawkins, ... week that explains one of the most popular and least understood books in the ... cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed it ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 million ... by frequent cessation in breathing. Oral appliances can offer significant relief to about ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... ... 2017 , ... Information about the technology: , Otomagnetics has ... prevention of a major side effect of chemotherapy in children. Cisplatin and carboplatin ... cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. Hearing ...
Breaking Medicine News(10 mins):